Stereochemistry | ABSOLUTE |
Molecular Formula | C28H39NO5 |
Molecular Weight | 469.613 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C(CN1CCOCC1)OC2=CC=C(C=C2)[C@H]3CC[C@@]4(CC3)OO[C@@]5(O4)C6CC7CC(C6)CC5C7
InChI
InChIKey=XLCNVWUKICLURR-WMORPJFDSA-N
InChI=1S/C28H39NO5/c1-3-26(31-14-11-29-9-12-30-13-10-29)4-2-22(1)23-5-7-27(8-6-23)32-28(34-33-27)24-16-20-15-21(18-24)19-25(28)17-20/h1-4,20-21,23-25H,5-19H2/t20?,21?,23-,24?,25?,27-,28-
Originator
Approval Year
AUC
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Sourcing
PubMed
Patents
Sample Use Guides
In clinical trials, Artefenomel is administered in 800 mg doses in loose combination with Piperaquine phosphate doses of either 640, 960, 1440 mg
Route of Administration:
Oral
Asexual parasites were seeded at a density of 0.5% parasitemia in 3% hematocrit in a black 384-well plate in 30 μL of culture medium, and 30 μL of diluted compound was added. Following a 72 h incubation at 37°C, 98% humidity, 93% N2, 4% CO2 and 3% O2, the increase in parasitemia was assessed using the modified Plasmodium lactate dehydrogenase assay.
Artefenomel was diluted in DMSO and subsequently in culture medium to reach a final DMSO concentration of 0.1%.
ACTIVE MOIETY
SALT/SOLVATE (PARENT)